Literature DB >> 22781677

Incorporating biomarkers into clinical trial designs: points to consider.

Edward Bradley1.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22781677     DOI： 10.1038/nbt.2296

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  11 in total

1.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

Review 2.  Integrating predictive biomarkers and classifiers into oncology clinical development programmes.

Authors:  Robert A Beckman; Jason Clark; Cong Chen
Journal:  Nat Rev Drug Discov       Date:  2011-09-30       Impact factor: 84.694

3.  Parallel paths to predictive biomarkers in oncology: Uncoupling of emergent biomarker development and phase III trial execution.

Authors:  Robert Sikorski; Bin Yao
Journal:  Sci Transl Med       Date:  2009-12-09       Impact factor: 17.956

4.  I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.

Authors:  A D Barker; C C Sigman; G J Kelloff; N M Hylton; D A Berry; L J Esserman
Journal:  Clin Pharmacol Ther       Date:  2009-05-13       Impact factor: 6.875

5.  Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.

Authors:  Andrew J Vickers; Vennus Ballen; Howard I Scher
Journal:  Clin Cancer Res       Date:  2007-02-02       Impact factor: 12.531

6.  Changing end points in breast-cancer drug approval--the Avastin story.

Authors:  Ralph B D'Agostino
Journal:  N Engl J Med       Date:  2011-06-27       Impact factor: 91.245

7.  A time to keep and a time to cast away categories of tumor response.

Authors:  Michael L Maitland; Robert R Bies; Jeffrey S Barrett
Journal:  J Clin Oncol       Date:  2011-07-05       Impact factor: 44.544

8.  Some design issues in trials of microbicides for the prevention of HIV infection.

Authors:  Thomas R Fleming; Barbra A Richardson
Journal:  J Infect Dis       Date:  2004-07-20       Impact factor: 5.226

Review 9.  Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.

Authors:  Volker Heinemann; Sebastian Stintzing; Thomas Kirchner; Stefan Boeck; Andreas Jung
Journal:  Cancer Treat Rev       Date:  2008-12-30       Impact factor: 12.111

Review 10.  Improved endpoints for cancer immunotherapy trials.

Authors:  Axel Hoos; Alexander M M Eggermont; Sylvia Janetzki; F Stephen Hodi; Ramy Ibrahim; Aparna Anderson; Rachel Humphrey; Brent Blumenstein; Lloyd Old; Jedd Wolchok
Journal:  J Natl Cancer Inst       Date:  2010-09-08       Impact factor: 13.506
View more
  7 in total

Review 1.  Drugs' development in acute heart failure: what went wrong?

Authors:  Vincenzo Teneggi; Nithy Sivakumar; Deborah Chen; Alex Matter
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

2.  Creative trial design in RA: optimizing patient outcomes.

Authors:  Maya H Buch; Sue Pavitt; Mahesh Parmar; Paul Emery
Journal:  Nat Rev Rheumatol       Date:  2013-02-05       Impact factor: 20.543

Review 3.  The Importance of Biopsy in the Era of Molecular Medicine.

Authors:  Etay Ziv; Jeremy C Durack; Stephen B Solomon
Journal:  Cancer J       Date:  2016 Nov/Dec       Impact factor: 3.360

Review 4.  Advances in the design of nanomaterial-based electrochemical affinity and enzymatic biosensors for metabolic biomarkers: A review.

Authors:  Leila Farzin; Mojtaba Shamsipur; Leila Samandari; Shahab Sheibani
Journal:  Mikrochim Acta       Date:  2018-05-02       Impact factor: 5.833

Review 5.  Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Ruwanthi Kolamunnage-Dona; Andrea L Jorgensen
Journal:  J Pers Med       Date:  2017-01-25

Review 6.  Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.

Authors:  Miranta Antoniou; Andrea L Jorgensen; Ruwanthi Kolamunnage-Dona
Journal:  PLoS One       Date:  2016-02-24       Impact factor: 3.240

7.  Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.

Authors:  Kyoungmin Lee; So Jung Lee; Shinkyo Yoon; Baek-Yeol Ryoo; Sang-We Kim; Sang Hyun Choi; Sang Min Lee; Eun Jin Chae; Yangsoon Park; Se-Jin Jang; Soo-Yeon Park; Young-Kwang Yoon; Seong Ho Park; Tae Won Kim
Journal:  PLoS One       Date:  2019-08-12       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.